The abstract is read at the publisher; the summary is JClub's.
Among 14,362 psoriatic arthritis patients starting their first biologic or targeted synthetic DMARD in 5 Nordic registries, 2% met difficult-to-manage criteria.
- Why it matters: EULAR’s framework for difficult-to-manage and treatment-refractory PsA needs real-world prevalence estimates and patient characteristics, especially in routine care.
- What they did: In a registry cohort (1999–2020) with median 6.3 years follow-up, investigators applied stepwise, registry-based components including multiple b/tsDMARD discontinuations, problematic symptoms, and persistent activity.
- The result: Treatment-refractory disease was found in 1.2% of patients, and both groups showed higher prevalence of women, depression, and opioid use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.